Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$13.52 USD
-0.23 (-1.64%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $14.82 +1.31 (9.66%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EWTX 13.52 -0.23(-1.64%)
Will EWTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Other News for EWTX
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
Raymond James Initiates Coverage on Edgewise Therapeutics (EWTX) with Strong Buy
Edgewise Therapeutics initiated with bullish view at Raymond James, here's why
PERCEPTIVE ADVISORS LLC Increases Stake in Praxis Precision Medicines Inc